Phase 1 Study Of PF-06863135, A BCMA-CD3 Bispecific Antibody, In Relapsed/Refractory Multiple Myeloma

What's the purpose of this trial?

The goal of this trial is to determine which dose level of PF-06863135 is safest, best tolerated, and works best when given by itself to patients with relapsed/refractory multiple myeloma.

This trial is currently open and accepting patients.

What's being studied?

  • PF-06863135 is a B-Cell Maturation Antigen (BCMA) CD-3 bispecific antibody being tested in multiple myeloma.

What will happen during the trial?

This phase 1 trial is being planned and conducted in two different parts, dose escalation (Part 1) and dose expansion (Part 2). Patients participating in Part 1 will receive different dose levels of PF-06863135. Patients participating in Part 2 will receive the dose of PF-06863135 determined to be safest in Part 1. Other drugs may be given with PF-06863135 depending on when you join the trial.

All patients participating in Part 1 must receive their first dose of PF-06863135 during a hospitalization on days 1-3 of their first cycle. Depending on how patients respond to PF-06863135, and whether they develop side effects, researcher may decide to give a priming dose of PF-06863135, which would be one single dose given in the hospital before you receive other scheduled treatments in the trial. Patients participating in Part 2 may or may not need to be hospitalized during their first dose of PF-06863135.

PART 1 – Dose Escalation

In this part of the trial, researchers are trying to determine the dose of PF-06863135 that is safest and best tolerated by itself. The dose of PF-06863135 you will receive, and whether you receive any other drugs with it, depends on when you join the trial. Once a certain number of patients have safely received a dose of PF-06863135, researchers may decide to give the next group of patients an increased dose. Researchers plan to have approximately 70 patients participate in this part of the trial.

  • PF-06863135 as monotherapy (Currently Accepting Patients)
    • Patients participating in this part of the trial will receive PF-06863135 through an IV or as a subcutaneous (SC) injection on days 1, 8, and 15 of 21-day cycles.

After researchers determine the best dose of PF-06863135 in each group, Part 2 of the trial will begin to enroll patients.

PART 2 – Dose Expansion

Dose expansion is not currently open to enrollment. In this part of the trial, researchers will give a larger group of participants the best dose of PF-06863135 from Part 1 by itself. Researchers plan to have approximately 80 patients participate in this part of the trial.

Patients can continue to participate in the study as long as they don’t develop bad side effects and their myeloma doesn’t get worse.

Additional Trial Information

Phase 1

Enrollment: 80 patients (estimated)

View More

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required. Create your account or call us today for help (888) 828-2206.

  • Patients must have relapsed/refractory multiple myeloma
  • Patient’s myeloma must have gotten worse while taking a proteasome inhibitor, immunomodulatory drug, and an anti-CD38 therapy (or patients are unable to take these therapies)
  • Patients must have adequate bone marrow, kidney and liver function
  • Patients must not have a history of active autoimmune disease
  • Patients must not have had a stem cell transplant within 3 months of joining the study
  • Patients must not have had an anti CD-38 therapy in the last 30 days before joining the study, and must have had an appropriate washout period from their previous systemic therapy
View Additional Criteria

Published Results

Pfizer Reports Positive Clinical Data for BCMA-CD3 Bispecific Antibody (PF-06863135) in Multiple Myeloma

December 07, 2020

The primary objectives of this portion of the study were to assess safety and tolerability of PF-06863135 administered subcutaneously, to determine the maximum tolerated dose, and to select the recommended Phase 2 dose. In the study, no dose-limiting toxicities were observed across any of the subcutaneous dose levels evaluated (80 to 1,000 μg/kg weekly) during dose escalation. Cytokine release syndrome (CRS) was reported in 73.3% of patients and was limited exclusively to grade 1 (56.7%) or grade 2 (16.7%). Grade 3 or higher adverse events (AEs) occurring in more than 10% of patients included lymphopenia (53.3%), neutropenia (26.7%), thrombocytopenia (16.7%) and anemia (16.7%).

The overall response rate (ORR) was 80% among the 20 patients treated in cohorts across the efficacious dose range of 215 to 1,000 μg/kg weekly. Among these 20 patients, six achieved stringent complete response or complete response, three achieved very good partial response, and six achieved partial response. Three responding patients had received at least one prior BCMA-targeted therapy. At the highest dose level of 1,000 μg/kg, the ORR was 83% (5/6 patients). Based on these data, 1,000 μg/kg weekly is the recommended Phase 2 dose.

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.


Moores Cancer Center UC San Diego Health

La Jolla, CA

Open and Accepting


Northside Hospital

Atlanta, GA

Open and Accepting


University of Chicago Medicine Comprehensive Cancer Center

Chicago, IL

Open and Accepting


Holden Comprehensive Cancer Center University of Iowa Hospitals and Clinics

Iowa City, IA

Open and Accepting


Ochsner Medical Center

Jefferson, LA

Open and Accepting

Ochsner Foundation Clinic

Jefferson, LA

Open and Accepting


Massachusetts General Hospital

Boston, MA

Open and Accepting

New York

Memorial Sloan Kettering Cancer Center

New York, NY

Open and Accepting

North Carolina

Duke Cancer Center Duke University Medical Center

Durham, NC

Open and Accepting


Baylor Charles A. Sammons Cancer Center Baylor Scott & White Health

Dallas, TX

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

SparkCures is working closely with Pfizer to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors